Dimethylamino Acid Esters as Biodegradable and Reversible Transdermal Permeation Enhancers: Effects of Linking Chain Length, Chirality and Polyfluorination
- 303 Downloads
Series of N,N-dimethylamino acid esters was synthesized to study their transdermal permeation-enhancing potency, biodegradability and reversibility of action. Effects of chirality, linking chain length and polyfluorination were investigated.
Materials and Methods
In vitro activities were evaluated using porcine skin and four model drugs—theophylline, hydrocortisone, adefovir and indomethacin. Biodegradability was determined using porcine esterase, reversibility was measured using electrical resistance.
No differences in activity were found between (R), (S) and racemic dodecyl 2-(dimethylamino)propanoate (DDAIP). Substitution of hydrocarbon tail by fluorocarbon one resulted in loss of activity. Replacement of branched linking chain between nitrogen and ester of DDAIP by linear one markedly improved penetration-enhancing activity with optimum in 4–6C acid derivatives. Dodecyl 6-(dimethylamino)hexanoate (DDAK) was more potent than clinically used skin absorption enhancer DDAIP for theophylline (enhancement ratio of DDAK and DDAIP was 17.3 and 5.9, respectively), hydrocortisone (43.2 and 11.5) and adefovir (13.6 and 2.8), while DDAIP was better enhancer for indomethacin (8.7 and 22.8). DDAK was rapidly metabolized by porcine esterase, and displayed low acute toxicity. Electrical resistance of DDAK-treated skin barrier promptly recovered to control values.
DDAK, highly effective, broad-spectrum, biodegradable and reversible transdermal permeation enhancer, is promising candidate for future research.
KEY WORDSbiodegradability permeation enhancers reversibility structure–activity relationships transdermal drug delivery
This work was supported by the Centre for New Antivirals and Antineoplastics (1M0508), the Ministry of Education of the Czech Republic (MSM0021620822) and the Grant Agency of the Charles University (286/2006/B-CH/FaF).
- 7.T. M. Suhonen, L. Pirskanen, M. Raisanen, K. Kosonen, J. H. Rytting, P. Paronen, and A. Urtti. Transepidermal delivery of beta-blocking agents: Evaluation of enhancer effects using stratum corneum lipid liposomes. J. Control. Release. 43:251–259 (1997). doi: 10.1016/S0168-3659(96)01495-2.CrossRefGoogle Scholar
- 10.N. Buyuktimkin, S. Buyuktimkin, and J. H. Rytting. Alkyl N,N-Disubstituted-Amino acetates. In E. W. Smith, and H. I. Maibach (eds.), Percutaneous Penetration Enhancers, CRC, New York, 1995, pp. 91–102.Google Scholar
- 12.W. Pfister, M. Li, and D. Frank. Development of the novel permeation enhancers dodecyl-2-N,N-dimethylaminopropionate (DDAIP) and HCl salt: physiochemical properties, preclinical safety and in vitro permeation enhancement. AAPS J. 8:(2006).Google Scholar
- 13.E. Touitou, B. Godin, T. R. Kommuru, M. I. Afouna, and I. K. Reddy. Transport of chiral molecules across the skin. In I. K. Reddy, and R. Mehvar (eds.), Chirality in Drug Design and Development, Marcel Dekker, New York, 2004, pp. 67–99.Google Scholar
- 22.K. Vavrová, K. Lorencová, J. Novotný, A. Holý, and A. Hrabálek. Permeation enhancer dodecyl 6-(dimethylamino)hexanoate increases transdermal and topical delivery of adefovir; influence of pH, ion-pairing and skin species. Eur. J. Pharm. Biopharm. 70:901–907 (2008), doi: 10.1016/j.ejpb.2008.07.002
- 23.A. Hrabalek, P. Dolezal, K. Vavrova, J. Zbytovska, T. Holas, J. Klimentova, and J. Novotny. Synthesis and enhancing effect of transkarbam 12 on the transdermal delivery of theophylline, clotrimazole, flobufen, and griseofulvin. Pharm. Res. 23:912–919 (2006). doi: 10.1007/s11095-006-9782-y.PubMedCrossRefGoogle Scholar
- 24.A. F. Abdel-Magid, K. G. Carson, B. D. Harris, C. A. Maryanoff, and R. D. Shah. Reductive amination of aldehydes and ketones with sodium triacetoxyborohydride. Studies on direct and indirect reductive amination procedures. J. Org. Chem. 61:3849–3862 (1996). doi: 10.1021/jo960057x.PubMedCrossRefGoogle Scholar
- 27.A. Williams. Alternative membranes for in-vitro studies. Transdermal and Topical Drug Delivery: From Theory to Clinical Practice, Pharmaceutical Press, London, 2003, pp. 54–58Google Scholar
- 29.W. J. Fasano, S. C. Carpenter, S. A. Gannon, T. A. Snow, J. C. Stadler, G. L. Kennedy, R. C. Buck, S. H. Korzeniowski, P. M. Hinderliter, and R. A. Kemper. Absorption, distribution, metabolism, and elimination of 8–2 fluorotelomer alcohol in the rat. Toxicol. Sci. 91:341–355 (2006). doi: 10.1093/toxsci/kfj160.PubMedCrossRefGoogle Scholar
- 39.A. Holy, J. Gunter, H. Dvorakova, M. Masojidkova, G. Andrei, R. Snoeck, J. Balzarini, and E. De Clercq. Structure-antiviral activity relationship in the series of pyrimidine and purine N-[2-(2-phosphonomethoxy)ethyl] nucleotide analogues. 1. Derivatives substituted at the carbon atoms of the base. J. Med. Chem. 42:2064–2086 (1999). doi: 10.1021/jm9811256.PubMedCrossRefGoogle Scholar